Search results for "hbv"

showing 10 items of 95 documents

Traditional Chinese Medicine (TCM) for fibrotic liver disease: Hope and hype

2014

Liver Cirrhosismedicine.medical_specialtyCirrhosisMEDLINEHolistic HealthTraditional Chinese medicineHolistic healthGastroenterologyHepatitisLiver diseaseFibrosisInternal medicineChinese traditionalHBVmedicineHumansMedicine Chinese TraditionalIntensive care medicineInflammationHepatitisClinical Trials as TopicHerbHepatologybusiness.industryNASHmedicine.diseaseFibrosisTCMCirrhosisLiverHCVCollagenAntifibroticbusinessDrugs Chinese HerbalJournal of Hepatology
researchProduct

Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop

2011

Abstract The Italian recommendations for the therapy of hepatitis B virus (HBV)-related disease were issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was approved for antiviral treatment. The introduction of this important new drug has called for the current guidelines update, which includes some additional revisions: (a) the indication for therapy is extended to mild liver fibrosis and the indication for treatment is graded as “possible”, “optional” or “mandatory” according to the fibrosis stage; (b) two different treatment strategies are described: first line definite duration treatment with interferon, long-term treatment of indefinite duration with NA; (c) the…

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularOrganophosphonateschronic hepatitis B The Italian recommendations for the therapy of hepatitis B Tenofovir Adefovir Cirrhosis Telbivudine Lamivudine Entecavirmedicine.disease_causeAntiviral Agentsadefovir; cirrhosis; entecavir; hbv; lamivudine; telbivudine; tenofovirHepatitis B ChronicInternal medicineTelbivudinemedicineAdefovirHBVHumansStage (cooking)TenofovirHepatitis B virusHepatologybusiness.industryAdenineLiver NeoplasmsGastroenterologyLamivudineEntecavirmedicine.diseaseVirologyItalyHepatocellular carcinomaReverse Transcriptase InhibitorsInterferonsbusinessmedicine.drug
researchProduct

The risk of hepatocellular carcinoma in HBV cirrhosis is affected by polymorphisms of the MERTK gene

2014

MERTK GeneCirrhosisHepatologybusiness.industryHepatocellular carcinomaGastroenterologyCancer researchMedicineHCC HBV MERTK Gene Polymorphismsbusinessmedicine.diseaseDigestive and Liver Disease
researchProduct

Occult hepatitis B virus infection

2000

Many studies have shown that hepatitis B virus infection may also occur in hepatitis B surface antigen-negative patients. This occult infection has been identified both in patients with cryptogenic liver disease and in patients with hepatitis C virus-related chronic hepatitis, and much evidence suggests that it may be a risk factor of hepatocellular carcinoma development. However several aspects of this occult infection remain unclear such as its prevalence and the factor(s) involved in the lack of circulating hepatitis B surface antigen. Moreover, it is uncertain whether the occult hepatitis B virus infection may contribute to chronic liver damage, considering that it is usually associated…

MaleACUTE VIRAL-HEPATITISPOSTTRANSFUSION HEPATITISHBV SURFACE-ANTIGENComorbidityHBV genome HBsAg-negative liver DNA liver diseasemedicine.disease_causeSeverity of Illness IndexSEROLOGICAL MARKERS; TRANSPLANT RECIPIENTS; POSTTRANSFUSION HEPATITIS; HEPATITIS C VIRUS; HEPATOCELLULAR-CARCINOMA; HBV SURFACE-ANTIGEN; ACUTE VIRAL-HEPATITIS; CHRONIC LIVER-DISEASE; POLYMERASE CHAIN-REACTION; occult hepatitis B virus infectionLiver diseaseCHRONIC LIVER-DISEASEHEPATOCELLULAR-CARCINOMAChronic/diagnosis* Hepatitis BDifferential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis Bhbsag-negative; hbv genome; liver disease; liver dnaIncidenceHepatocellular/diagnosis CarcinomaLiver NeoplasmsGastroenterologyHepatitis CHepatitis BPOLYMERASE CHAIN-REACTIONPrognosisChronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexCarcinoma Hepatocellular/diagnosis Carcinoma Hepatocellular/epidemiology* Comorbidity DNA Viral/analysis Diagnosis Differential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis B Chronic/diagnosis* Hepatitis B Chronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexHepatocellular carcinomaDisease Progressionhbv genomeFemaleliver diseaseCarcinoma HepatocellularTRANSPLANT RECIPIENTSRisk AssessmentDiagnosis Differentialoccult hepatitis B virus infectionHepatitis B ChronicViral/analysis DiagnosismedicineHumansRisk factorHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryCarcinomaHEPATITIS C VIRUShbsag-negativeliver dnamedicine.diseaseOccultVirologyHepatocellular/epidemiology* Comorbidity DNASEROLOGICAL MARKERSViral replicationImmunologyDNA Viralbusiness
researchProduct

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year…

2020

BackgroundLimited data exist regarding tenofovir disoproxil fumarate (TDF) safety and effectiveness in chronic hepatitis B virus-infected (CHB) patients with renal impairment (RI).AimsTo compare real-world data on renal safety and effectiveness of TDF vs entecavir (ETV) in CHB patients with moderate-to-severe RI.MethodsRetrospective, non-interventional, cohort study analysing medical records for TDF/ETV-treated CHB patients (54 European centres). Included patients experienced moderate-to-severe RI (creatinine clearance 20-60 mL/min [Cockcroft-Gault]) either before TDF/ETV initiation ('before' subgroup [baseline = treatment initiation]) or after TDF/ETV initiation ('after' subgroup [baseline…

MaleAdultmedicine.medical_specialtyGuanineTenofovirMEDLINEAntiviral AgentsVirus03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicRetrospective StudieInternal medicine80 and overHBVMedicineHumansPharmacology (medical)030212 general & internal medicineRenal InsufficiencyYoung adultAdult; Aged; Aged 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir; Treatment Outcome; Young AdultChronicTenofovirAgedRetrospective StudiesAged 80 and overAntiviral AgentHepatologybusiness.industryGastroenterologyvirus diseasesRetrospective cohort studyEntecavirHepatitis BMiddle Agedmedicine.diseaseHepatitis BTreatment OutcomeCohort030211 gastroenterology & hepatologyFemalebusinessmedicine.drugHuman
researchProduct

Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term…

2002

Abstract Immunoglobulin G (IgG) antibody titres against pertussis antigens, Bordetella pertussis-specific proliferation and cytokine production by peripheral blood mononuclear cells (PBMCs) were evaluated at the age of 5–6 years in 13 children who had been pre-term infants with a gestational age (GA) of ≤31 weeks, 10 who had been pre-term infants with a GA of 32–37 weeks, and 15 who had been term infants with a GA of 38–42 weeks. All of the infants had been immunised with a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine (DTaP–HBV) at 3, 5, and 11 months of post-natal age. Our results show that the long-term immune responses induced by primary pertussi…

MaleCellular immunityBordetella pertussisTime FactorsHepatitis B vaccineWhooping CoughImmunization SecondaryIn Vitro TechniquesLymphocyte ActivationBordetella pertussisPertussismedicineHumansHepatitis B VaccinesChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleWhooping coughHaemophilus VaccinesImmunity CellularPre-term infantsGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaDTaP-HBV vaccine; Pertussis; Pre-term infantsAge FactorsInfant NewbornPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationAntibodies BacterialVaccinationInfectious DiseasesCase-Control StudiesChild PreschoolImmunoglobulin GImmunologybiology.proteinDTaP-HBV vaccineCytokinesMolecular MedicineFemaleAntibodybusinessInfant PrematureVaccine
researchProduct

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

2017

Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child…

MaleCirrhosisSettore MED/09 - Medicina InternaAlcohol abuseAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Internal Medicinemedicine.disease_causeGastroenterology0302 clinical medicineRisk FactorsEpidemiologyHBV030212 general & internal medicineLiver Neoplasmsvirus diseasesMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver NeoplasmHepatocellular carcinomaHCV030211 gastroenterology & hepatologyAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Aged; Alcoholism; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Internal MedicineFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusLiver CirrhosiAlcohol abuseLiver cirrhosis epidemiology03 medical and health sciencesInternal medicinemedicineInternal MedicineHumansDecompensationAgedHepatitis B virusCross-Sectional Studiebusiness.industryRisk FactorCarcinomaHepatocellularmedicine.diseaseCross-Sectional StudiesLiver cirrhosisEtiologybusiness
researchProduct

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

2003

Background & Aims: Occult hepatitis B virus (HBV) infection is characterized by persistence of HBV DNA into the tissue of hepatitis B surface antigen-negative individuals. The clinical relevance of this peculiar infection is still under debate. In particular, the impact of occult HBV infection in cases of hepatocellular carcinoma (HCC) is uncertain. We investigated the prevalence and molecular status of occult HBV in patients with HCC. Methods: We tested tumor tissues from 107 patients with HCC and the corresponding nontumor liver tissue from 72 of these patients for HBV DNA. We also examined liver specimens from 192 patients with chronic hepatitis. All cases were hepatitis B surface antige…

MaleHBV; HCC; occultHepatitis B virusCarcinoma HepatocellularOCCULT HEPATITIS B VIRUS INFECTION; HEPATOCELLULAR CARCINOMA; HBV DNA; TUNOR AND NONTUMOR LIVER TISSUES; HBV TRANSCRIPTS; HBV COVALENTLY CLOSED CIRCULAR DNA; INTEGRATED AND EPISOMAL HBV DNATranscription GeneticOCCULT HEPATITIS B VIRUS INFECTIONHBV TRANSCRIPTSGenome ViralBiologyVirus Replicationmedicine.disease_causeChronic liver diseaseHepatitis B ChronicmedicineCarcinomaHBVHumansHEPATOCELLULAR CARCINOMATUNOR AND NONTUMOR LIVER TISSUESHCCAgedHepatitis B virusHepatologyINTEGRATED AND EPISOMAL HBV DNALiver NeoplasmsGastroenterologyvirus diseasescccDNAMiddle AgedHepatitis Bmedicine.diseaseOccultVirologydigestive system diseaseshepatitis B surface antigenLiverViral replicationHBV DNAoccultHepatocellular carcinomaDNA ViralImmunologyFemaleHBV COVALENTLY CLOSED CIRCULAR DNAInfection OBI
researchProduct

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genot…

2019

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA <20 IU/mL. The primary endpoint was proportion of patients with ≥50% decline in serum HBsAg by the end of the 48-week add-on phase. Seventy patients received treatment, 11 were withdrawn at week 24 for no decrease in HBsAg, and 14 withdrew for other reasons. Response rate (per-protocol population) was 67.4% (29/43) at…

MaleHBsAgGastroenterologyPolyethylene Glycolschronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatment; Hepatology; Infectious Diseases; Virology0302 clinical medicineInterferonGenotypeHBVHepatitis B e Antigenspeginterferonchronic hepatitis b; hbeag-negative; nucleos(t)ide analogues; peginterferon; treatment; adult; antiviral agents; drug administration schedule; drug therapy combination; female; genotype; hepatitis b e antigens; hepatitis b virus; hepatitis b chronic; humans; interferon-alpha; male; middle aged; nucleosides; polyethylene glycols; recombinant proteins; treatment outcomeeducation.field_of_studytreatmentnucleos(t)ide analoguesvirus diseasesNucleosidesMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious Diseasesnucleos(t)ide analogueHBeAg030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPeginterferon alfa-2amedicine.drugAdultHepatitis B virusmedicine.medical_specialtyGenotypeCombination therapyPopulationHBeAg-negativeInfectious DiseaseHBeAg-negative; chronic hepatitis B; nucleos(t)ide analogues; peginterferon; treatmentchronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatmentAntiviral AgentsDrug Administration Schedule03 medical and health sciencesHepatitis B ChronicInternal medicineVirologymedicineHumanschronic hepatitis BeducationHepatologybusiness.industryInterferon-alphaConfidence intervalbusiness
researchProduct

One‐quarter of chronic hepatitis D patients reach HDV‐RNA decline or undetectability during the natural course of the disease

2021

BACKGROUND Spontaneous HDV-RNA fluctuations, assessed by nonstandardised in-house assays, have been reported during the course of chronic hepatitis delta (CHD). AIMS To evaluate changes in serum HDV-RNA concentrations in untreated CHD patients and correlate these changes with other HBV markers. METHODS A total of 323 consecutive serum samples from 56 CHD patients (detectable HDV-RNA) followed for >3 years were retested for HDV-RNA levels by a sensitive technique using the first WHO international HDV-RNA standard. Quantitative HBsAg, HBV-DNA, and HBV-RNA were also determined. RESULTS Most participants were male, middle-aged, white European, and HBeAg-negative (82%). Almost half had liver cir…

MaleHepatitis B virusHBsAgmedicine.medical_specialtyCirrhosisHepatitis D ChronicvirusesHbv markersDiseaseGastroenterology03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicinemedicineHumansPharmacology (medical)030212 general & internal medicineNatural courseHepatitis B Surface AntigensHepatologybusiness.industryGastroenterologyvirus diseasesMiddle Agedbiochemical phenomena metabolism and nutritionSerum samplesmedicine.diseaseHepatitis DDNA ViralRNAQuantitative hbsag030211 gastroenterology & hepatologyHepatitis Delta VirusbusinessAlimentary Pharmacology &amp; Therapeutics
researchProduct